Reviewer's report

Title: Achieving sustained virologic response in hepatitis C: A review of the clinical, economic and quality of life benefits

Version: 2 Date: 11 October 2014

Reviewer: Sylvie Deuffic-Burban

Reviewer's report:

Major Compulsory Revisions: none

Minor Essential Revisions:
- Although the editor will improve the presentation of the manuscript, I would like to emphasize that it is not good:
  1/ the first 16 pages are in landscape orientation
  2/ some pages are suddenly interrupted in the middle of a line with a jump of pages
  3/ all the pages are numbered "39"
  4/ unsuitable formatting for references: e.g. replacing 5, 6, 7, 8 by 5-8

- Methods, 1st paragraph: the authors should justify why they have chosen a minimum enrollment of 100 patients for studies to be included, why 100? How many studies have been excluded because of this limit?

- Figure 1: spelling mistake “moninfection” to be replaced by “monoinfection”

- Discussion: the authors should discuss the lack of data on the impact of SVR on the long-term quality of life. We do not know whether these benefits are maintained over the long term. Some "patients" report a feeling of abandonment, up to a depressive state, because no longer monitored regularly as before.

Discretionary Revisions:

- Tables: what is the logic of chronology? The studies are not sorted alphabetically or by year of publication, or by country or by type of study ... Authors should order them by country, I think, to facilitate comparison.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received research grants from Roche, Janssen and Schering-Plough/Merck, and consultancy honoraria from Abbvie, Bristol-Myers
Squibb, Gilead, Janssen, Schering-Plough/Merck and Glaxo Smith Kline.